In conclusion, we characterized the genomic landscape of solid tumor patients with ALK, ROS1, and NTRK fusions and 62 novel fusions were discovered, which may provide more clinically actionable targets for cancer therapy to a great extent. This evidence concerns the gene ROS1 and cancer.